Jim Cramer Expresses Bullishness on Zimmer's Acquisition of Monogram Technologies

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the stocks on Jim Cramer’s radar. Cramer discussed the company’s latest acquisition announcement and commented:

“We got some sizable deals today across a bunch of different industries and some smaller ones too, like Zimmer Biomet, the medical device maker, announcing its plan to pay nearly $200 million upfront for Monogram Technologies, an orthopedics robot company with a set of semi-autonomous and fully autonomous robotic technologies that will be used to improve Zimmer’s main robotics platform called Rosa Robotics. I like this because the robotics surgery space is one of the most interesting corners of the healthcare sector.”

Zimmer Biomet (NYSE:ZBH) develops and markets medical technologies and orthopedic products used to treat bone, joint, and soft tissue conditions. The company’s portfolio includes implants, surgical tools, and digital health solutions. Oakmark Equity and Income Fund stated the following regarding Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in its second quarter 2025 investor letter:

“Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is a leading medical device company and a pure play in orthopedics. In our view, orthopedics is an attractive product category that should benefit from long-term tailwinds stemming from an aging population, greater activity levels among seniors and increased adoption of specialized robotics that improve surgical efficiency. In addition, market share within the space tends to be sticky, as physicians are typically trained to use leading brands like Zimmer Biomet, reinforcing long-standing brand loyalty. New management recently completed several multi-year initiatives that we think will streamline operations and reinvigorate product innovation. The market has yet to ascribe value to these improvements, providing the opportunity to initiate a position in a dominant, growing company at a discounted valuation to peers and the broader market.”

While we acknowledge the potential of ZBH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.